Jacopo Troisi1,2, Federica Facciotti3, Francesco Strati4, Meritxell Pujolassos1, Claudia Burrello5, Maria Rita Giuffrè5, Georgia Lattanzi5, Flavio Caprioli6,7. 1. Theoreo srl, Spin-off Company of the University of Salerno, Montecorvino Pugliano, Italy. 2. European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy. 3. Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. federica.facciotti@ieo.it. 4. Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. francesco.strati@ieo.it. 5. Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 6. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. 7. Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Abstract
BACKGROUND: The gut microbiota plays a central role in host physiology and in several pathological mechanisms in humans. Antibiotics compromise the composition and functions of the gut microbiota inducing long-lasting detrimental effects on the host. Recent studies suggest that the efficacy of different clinical therapies depends on the action of the gut microbiota. Here, we investigated how different antibiotic treatments affect the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in an experimental colitis model and in ex vivo experiments with human intestinal biopsies. RESULTS: Murine fecal donors were pre-treated with different antibiotics, i.e., vancomycin, streptomycin, and metronidazole before FMT administration to colitic animals. The analysis of the gut microbiome, fecal metabolome, and the immunophenotyping of colonic lamina propria immune cells revealed that antibiotic pre-treatment significantly influences the capability of the microbiota to control intestinal inflammation. Streptomycin and vancomycin-treated microbiota failed to control intestinal inflammation and were characterized by the blooming of pathobionts previously associated with IBD as well as with metabolites related to the presence of oxidative stress and metabolism of simple sugars. On the contrary, the metronidazole-treated microbiota retained its ability to control inflammation co-occurring with the enrichment of Lactobacillus and of innate immune responses involving iNKT cells. Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4+ T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10. CONCLUSIONS: Diverse antibiotic regimens affect the ability of the gut microbiota to control intestinal inflammation in experimental colitis by altering the microbial community structure and microbiota-derived metabolites. Video Abstract.
BACKGROUND: The gut microbiota plays a central role in host physiology and in several pathological mechanisms in humans. Antibiotics compromise the composition and functions of the gut microbiota inducing long-lasting detrimental effects on the host. Recent studies suggest that the efficacy of different clinical therapies depends on the action of the gut microbiota. Here, we investigated how different antibiotic treatments affect the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in an experimental colitis model and in ex vivo experiments with human intestinal biopsies. RESULTS:Murine fecal donors were pre-treated with different antibiotics, i.e., vancomycin, streptomycin, and metronidazole before FMT administration to colitic animals. The analysis of the gut microbiome, fecal metabolome, and the immunophenotyping of colonic lamina propria immune cells revealed that antibiotic pre-treatment significantly influences the capability of the microbiota to control intestinal inflammation. Streptomycin and vancomycin-treated microbiota failed to control intestinal inflammation and were characterized by the blooming of pathobionts previously associated with IBD as well as with metabolites related to the presence of oxidative stress and metabolism of simple sugars. On the contrary, the metronidazole-treated microbiota retained its ability to control inflammation co-occurring with the enrichment of Lactobacillus and of innate immune responses involving iNKT cells. Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBDpatients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4+ T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10. CONCLUSIONS: Diverse antibiotic regimens affect the ability of the gut microbiota to control intestinal inflammation in experimental colitis by altering the microbial community structure and microbiota-derived metabolites. Video Abstract.
Entities:
Keywords:
Antibiotics; FMT; Gut microbiota; IBD; iNKT
Authors: Brittany B Lewis; Charlie G Buffie; Rebecca A Carter; Ingrid Leiner; Nora C Toussaint; Liza C Miller; Asia Gobourne; Lilan Ling; Eric G Pamer Journal: J Infect Dis Date: 2015-04-28 Impact factor: 5.226
Authors: Tsutomu Matsubara; Naoki Tanaka; Kristopher W Krausz; Soumen K Manna; Dong Wook Kang; Erik R Anderson; Hans Luecke; Andrew D Patterson; Yatrik M Shah; Frank J Gonzalez Journal: Cell Metab Date: 2012-11-07 Impact factor: 27.287
Authors: Doina Georgescu; Alexandru Caraba; Ioana Ionita; Ana Lascu; Emil Florin Hut; Simona Dragan; Oana Elena Ancusa; Ioana Suceava; Daniel Lighezan Journal: Int J Womens Health Date: 2022-01-26